0R02 Stock Overview
A biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 3 more risks
Organovo Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.49 |
| 52 Week High | US$2.04 |
| 52 Week Low | US$0.45 |
| Beta | 0.61 |
| 11 Month Change | 7.15% |
| 3 Month Change | -6.62% |
| 1 Year Change | -70.45% |
| 33 Year Change | -91.98% |
| 5 Year Change | n/a |
| Change since IPO | -99.64% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0R02 | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | -0.3% | -1.3% |
| 1Y | -70.5% | -14.6% | 8.9% |
Return vs Industry: 0R02 underperformed the UK Biotechs industry which returned -14.6% over the past year.
Return vs Market: 0R02 underperformed the UK Market which returned 8.9% over the past year.
Price Volatility
| 0R02 volatility | |
|---|---|
| 0R02 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 8.3% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 9.5% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0R02's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: Insufficient data to determine 0R02's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 20 | n/a | www.organovo.com |
Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised of mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company’s lead candidate is FXR314, which is phase 2/3clinical trial for indication of inflammatory bowel disease with a clinical focus on ulcerative colitis; and completed phase 1 clinical trial for the indication of liver fibrosis with a clinical focus steatohepatitis.
Organovo Holdings, Inc. Fundamentals Summary
| 0R02 fundamental statistics | |
|---|---|
| Market cap | US$7.15m |
| Earnings (TTM) | -US$13.99m |
| Revenue (TTM) | US$73.00k |
97.9x
P/S Ratio-0.5x
P/E RatioIs 0R02 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0R02 income statement (TTM) | |
|---|---|
| Revenue | US$73.00k |
| Cost of Revenue | US$5.24m |
| Gross Profit | -US$5.16m |
| Other Expenses | US$8.82m |
| Earnings | -US$13.99m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.91 |
| Gross Margin | -7,072.60% |
| Net Profit Margin | -19,160.27% |
| Debt/Equity Ratio | 0% |
How did 0R02 perform over the long term?
See historical performance and comparison